Cargando…

Characterization of Binding and Inhibitory Properties of TAK-063, a Novel Phosphodiesterase 10A Inhibitor

Phosphodiesterase 10A (PDE10A) inhibition is a novel and promising approach for the treatment of central nervous system disorders such as schizophrenia and Huntington’s disease. A novel PDE10A inhibitor, TAK-063 [1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)-pyridazin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harada, Akina, Suzuki, Kazunori, Kamiguchi, Naomi, Miyamoto, Maki, Tohyama, Kimio, Nakashima, Kosuke, Taniguchi, Takahiko, Kimura, Haruhide
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376699/ https://www.ncbi.nlm.nih.gov/pubmed/25815469 http://dx.doi.org/10.1371/journal.pone.0122197

Ejemplares similares

Translational Development Strategies for TAK-063, a Phosphodiesterase 10A Inhibitor
por: Macek, Thomas A, et al.
Publicado: (2020)

Combined treatment with a selective PDE10A inhibitor TAK‐063 and either haloperidol or olanzapine at subeffective doses produces potent antipsychotic‐like effects without affecting plasma prolactin levels and cataleptic responses in rodents
por: Suzuki, Kazunori, et al.
Publicado: (2017)

S223. COMBINED TREATMENT WITH A SELECTIVE PDE10A INHIBITOR TAK-063 AND ANTIPSYCHOTICS AT SUBEFFECTIVE DOSES PRODUCES POTENT ANTIPSYCHOTIC-LIKE EFFECTS WITHOUT EXACERBATING SIDE EFFECTS PROFILE IN RODENTS
por: Suzuki, Kazunori, et al.
Publicado: (2018)

TAK-071, a muscarinic M(1) receptor positive allosteric modulator, attenuates scopolamine-induced quantitative electroencephalogram power spectral changes in cynomolgus monkeys
por: Kurimoto, Emi, et al.
Publicado: (2019)

Phosphodiesterase 10A Inhibition Leads to Brain Region-Specific Recovery Based on Stroke Type
por: Birjandi, Shirin Z., et al.
Publicado: (2020)

Correction to: Phosphodiesterase 10A Inhibition Leads to Brain Region-Specific Recovery Based on Stroke Type
por: Birjandi, Shirin Z., et al.
Publicado: (2020)

Preclinical characterization of AMPA receptor potentiator TAK‐137 as a therapeutic drug for schizophrenia
por: Tanaka, Maiko, et al.
Publicado: (2019)

A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor
por: Tsai, Max, et al.
Publicado: (2016)

Balanced Activation of Striatal Output Pathways by Faster Off-Rate PDE10A Inhibitors Elicits Not Only Antipsychotic-Like Effects But Also Procognitive Effects in Rodents
por: Harada, Akina, et al.
Publicado: (2019)

Strictly regulated agonist-dependent activation of AMPA-R is the key characteristic of TAK-653 for robust synaptic responses and cognitive improvement
por: Suzuki, Atsushi, et al.
Publicado: (2021)

A randomized, placebo-controlled, phase 1 study to evaluate the effects of TAK-063 on ketamine-induced changes in fMRI BOLD signal in healthy subjects
por: Yurgelun-Todd, Deborah A., et al.
Publicado: (2019)

Author Correction: Strictly regulated agonist-dependent activation of AMPA-R is the key characteristic of TAK-653 for robust synaptic responses and cognitive improvement
por: Suzuki, Atsushi, et al.
Publicado: (2021)

A Randomized Multiple Dose Pharmacokinetic Study of a Novel PDE10A Inhibitor TAK-063 in Subjects with Stable Schizophrenia and Japanese Subjects and Modeling of Exposure Relationships to Adverse Events
por: Goldsmith, Paul, et al.
Publicado: (2017)

P063 Optogenetics for Obstructive Sleep Apnea
por: Knapman, F, et al.
Publicado: (2021)

O063. Moyamoya disease and headache: case report
por: Tozzi, Elisabetta, et al.
Publicado: (2015)

LSD1 enzyme inhibitor TAK-418 unlocks aberrant epigenetic machinery and improves autism symptoms in neurodevelopmental disorder models
por: Baba, Rina, et al.
Publicado: (2021)

Macrophage Migration Inhibitory Factor as an Emerging Drug Target to Regulate Antioxidant Response Element System
por: Yukitake, Hiroshi, et al.
Publicado: (2017)

SAT-063 Polymicrobial Suppurative Thyroiditis Masquerading as Thyroid Storm
por: Finn, Erin E, et al.
Publicado: (2020)

Synthesis of hydroxyethyl tetrathiatriarylmethyl radicals OX063 and OX071
por: Poncelet, Martin, et al.
Publicado: (2019)

LBODP063 The Benefits Of Using Cgm For Intravenous Insulin Therapy
por: Bublik, Evgeniya, et al.
Publicado: (2022)

2-Amino-5-methylpyridinium picolinate 0.63-hydrate
por: Hemamalini, Madhukar, et al.
Publicado: (2010)

P063. Colloid cysts of the third ventricle: a case report
por: de Pasqua, Silvia, et al.
Publicado: (2015)

AB063. 63 cases of DCD experience in renal transplant recipients
por: Sun, Xu
Publicado: (2015)

O063 Impact of sleep deprivation on distributed team performance and cohesion
por: Greer, E, et al.
Publicado: (2022)

OC.06.3 POST-COVID-19 IRRITABLE BOWEL SYNDROME
por: Marasco, G., et al.
Publicado: (2023)

FRI063 Effectiveness Of Liraglutide In Treating Obesity And Improving Hepatic Steatosis
por: Alfadda, Assim Abdulaziz, et al.
Publicado: (2023)

Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury
por: Sisson, Thomas H., et al.
Publicado: (2018)

SUN-LB063 Peripheral Clock System Circadian Imbalance in Cushing's Disease
por: Soares, Vinicius, et al.
Publicado: (2019)

063 Autoimmunity and disease outcomes of COVID-19, lessons from vitiligo patients
por: Post, N., et al.
Publicado: (2022)

P063: Tackling VRE in a community hospital with teamwork and tenacity: lessons learned
por: Raggiunti, P, et al.
Publicado: (2013)

P063 Research on antifungal activity of a new azoles compound, YZJT-1903
por: Zhu, Shuo, et al.
Publicado: (2022)

SAT063 Dopaminergic Agonist Cabergoline Inhibits Autophagic Flux In Beta Pancreatic Cells
por: Francisco Mendez, Luis, et al.
Publicado: (2023)

Positron Emission Tomography Assessments of Phosphodiesterase 10A in Patients With Schizophrenia
por: Kubota, Manabu, et al.
Publicado: (2022)

TAK1ng control: TAK1 restrains NLRP3 activation
por: Mangan, Matthew Stephen, et al.
Publicado: (2018)

Search for new heavy quarks in proton-antiproton collisions at $\sqrt{s}$ = 0.63 TeV
por: Albajar, C, et al.
Publicado: (1990)

Double pomeron exchange studies in p$\overline{p}$ interactions at 0.63 TeV
por: Joyce, D, et al.
Publicado: (1993)

β-Li(0.37)Na(0.63)Fe(MoO(4))(2)
por: Souilem, Amira, et al.
Publicado: (2014)

SAT-LB063 The ZFP36 Family of RNA-Binding Proteins Regulate Human Steroidogenesis
por: Wellman, Kimberly, et al.
Publicado: (2019)

T‐495, a novel low cooperative M(1) receptor positive allosteric modulator, improves memory deficits associated with cholinergic dysfunction and is characterized by low gastrointestinal side effect risk
por: Mandai, Takao, et al.
Publicado: (2020)

The pyrochlore-type molybdate Pr(1.37)Ca(0.63)Mo(2)O(7)
por: Gall, P., et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_t5ggf6a6arpjiu15vhjhi51qnd